Bone Abstracts

Page 1 of about 2 results

ba0003OP11 | Clinical | ECTS2014

A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia

Carpenter Thomas , Imel Erik , Ruppe Mary , Weber Thomas , Klausner Mark , Wooddell Margaret , Kawakami Tetsuyoshi , Ito Takahiro , Zhang Xiaoping , Humphrey Jeffrey , Insogna Karl , Peacock Munro

see PP90....

0 shares

ba0003pp90 | Bone development/growth and fracture repair | ECTS2014

A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia

Carpenter Thomas , Imel Erik , Ruppe Mary , Weber Thomas , Klausner Mark , Wooddell Margaret , Kawakami Tetsuyoshi , Ito Takahiro , Zhang Xiaoping , Humphrey Jeffrey , Insogna Karl , Peacock Munro

Purpose: In X-linked hypophosphatemia (XLH), elevated serum FGF23 causes low serum phosphorus (Pi) and inappropriately normal 1,25-dihydroxyvitamin D (1,25(OH)2D) levels. We report safety, tolerability and biochemistry markers following single ascending dose administration of KRN23 in adults with XLH.Methods: 38 XLH subjects with baseline FGF23≥30 pg/ml were randomized to receive single doses of KRN23 (K) or placebo (P) either (0.003&#15...

0 shares

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more

Bone Abstracts

A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia

A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia

BiosciAbstracts